The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

MAY 4, 2021

This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumour types. Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study.

HR 52

HR Protein In-Vitro Medicine 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Luncheon presentations will be given by Andrew Bradbury, MB BS, PhD, Chief Scientific Officer, Specifica, and Stefanie Kall, Ph.D.,

Antibody 64

Antibody Engineer Protein Scientist 64

XTalks

NOVEMBER 20, 2020

The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2. Meanwhile, Indoor Biotechnologies has been working with Cardiff University’s School of Medicine on its test. At that point in time, 81 people tested positive for the virus.

Antibody 98

Antibody Immune Response Protein In-Vitro 98